GnRH agonists are effective in causing systemic hypoestrogenism to reduce the size of adenomyosis and improve adenomyosis-associated symptoms [153,154,155], whereas the side effects of GnRH agonists (menopausal symptoms) limit their use. This evidence concerns the gene GNRH1 and adenomyosis.